Drug Discovery World

MAY 30, 2024

Dr Pollock is the Chief Investigator of the LEGACY03 clinical trial, a study aiming to investigate lymph nodes and vaccination responses across age groups. RA: Could you tell us about the LEGACY03 trial? It is these differences in immune response, which have stimulated our research to improve vaccine design.

Vaccination 59

Vaccination Vaccine Scientist Clinical Trials 59

Drug Discovery World

NOVEMBER 30, 2022

The University of Queensland is set to take a second-generation molecular clamp vaccine to a proof-of-concept human trial. . million to support further development of the re-engineered technology for use in the global response to future disease outbreaks. . Clamp technology .

Vaccination 52

Vaccination Vaccine Immune Response Engineer 52

The Pharma Data

DECEMBER 30, 2020

The Phase I/II study results, together with recently generated preclinical data, indicate that ARCT-021 leads to a potent immune response to SARS-CoV-2, and demonstrates a differentiated biological profile whereby the immune response increases in the weeks following vaccination, the company said. Most Read Today.

Genome 52

Genome Genomics Immune Response Vaccination 52

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Freenome persists in getting strong financial support for its development work, with USD 270 million in new funds to push its cancer-detecting blood test via clinical trials and across the FDA’s finish line.

Vaccination 53

Vaccination Vaccine Research Trials 53

Drug Discovery World

JULY 17, 2023

While the human genome boasts around 23,000 genes, the average human gut encompasses approximately 2,000,000 genes. One involves sequencing all or part of the 16S gene unique to bacteria, while the other encompasses sequencing the entire bacterial genome—an approach known as “metagenomics.” REFERENCES Rosshart, S.

Bacteria 52

Bacteria Drugs Gene Immune Response 52

The Pharma Data

APRIL 8, 2021

The Company will share a Spotlight Theater Presentation: The Orchestrated Immune Response: Dynamic Forces Guiding Cancer Immunity , introducing a novel framework for understanding the role of the immune system in cancer, with the potential to reshape the way scientists develop medicines to counteract tumour growth.

DNA 52

DNA Medicine Genome Genomics 52

Drug Discovery World

MAY 6, 2024

billion on R&D during 2021, with Germany and Switzerland being the biggest contributors, and around one fourth of clinical trials worldwide were performed in Europe 1. The city is host to many innovative biotech companies, including relative newcomers Orexa, a company that recently launched its first Phase II clinical trial.

Drugs 59

Drugs Life Science Gene Editing Gene 59

Drug Discovery World

FEBRUARY 13, 2023

SB: Transcriptomics is the study of genomic RNA transcripts in a biological system. Diseases ranging from cancer to viral immune response, from cardiovascular to reproductive health, and from metabolic to nervous systems all have the potential to benefit from in-depth transcriptomics. SB: Certainly.

RNA 52

RNA Drugs Gene Expression Gene 52

The Pharma Data

JANUARY 11, 2021

In clinical trials, it could detect COVID-19 with 90%+ accuracy in about two minutes. . By the end of January, Johnson & Johnson is expected to deliver preliminary trial results for its one-dose COVID-19 vaccine candidate. . DalCor Pharmaceuticals initiated the Phase II dal-COVID trial of dalcetrapib for COVID-19.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

pharmaphorum

SEPTEMBER 22, 2022

Le Vert says Osivax’s technology differs, however, as it attacks the virus’ T-cells, making the vaccine more effective in the long term, and that clinical trials have shown promise. The beauty of that T-cell response is that you can actually access the internal parts of the virus,” Le Vert states.

Vaccination 97

Vaccination Vaccine Antibody Clinical Trials 97

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The study showed this broad immune response led to the complete clearance of the virus in a matter of days after infection of previously-vaccinated primates.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2). i,ii,iii,iv.

Antibody 52

Antibody Vaccination Vaccine Trials 52

XTalks

DECEMBER 17, 2021

And in healthcare and health research, trends towards increased digitization continued, including remote monitoring in clinical trials, use of wearable technologies and AI-based approaches to data collection, management and analysis. The results are promising and Moderna is set to go ahead with its planned Phase II trial for the vaccine.

Life Science 98

Life Science Vaccination Vaccine Trials 98

The Pharma Data

MARCH 16, 2021

1 lineage gained prominence in late 2020, with each carrying a number of genomic mutations. 1.351 carries another spike mutation E484K, which appears to evade the body’s immune response, possibly diminishing vaccine efficacy. Variants of B.1.1.7, 1.351 and P.1 2,3 Another variant, B.1.351, 4 Variant P.1,

Antibody 52

Antibody Clinical Trials Clinical Trials Vaccination 52

Drug Discovery World

APRIL 14, 2023

He is being recognised for his celebrated contributions to the understanding and targeting of pancreas cancer metastasis, including work that has assisted with the development of minnelide, a pro-drug of triptolide for the treatment of pancreas and gastrointestinal cancers that is currently in Phase II clinical trials.

Genetics 52

Genetics Research Medicine Clinical Research 52

Pharma Marketing Network

DECEMBER 21, 2020

Almost two decades after the human genome was sequenced, a trickle of new genetic medicines (i.e., With over 100 late-stage gene therapy trials underway and an increasing number of gene-editing technologies entering trials, it’s clear that this trickle will soon become a torrent.

Genetics 52

Genetics Medicine Gene Therapy Marketing 52

World of DTC Marketing

DECEMBER 29, 2020

Both the Pfizer and Moderna vaccines copied RNA sequence from the virus genome and found a way to manufacture it at scale with high-level processes and quality control. Another consideration is that while in traditional vaccine development, clinical trials are carried out in sequence. 1455NO-HEALTH-CORONAVIRUS_VACCINES_PFIZER_O_.

Vaccination 307

Vaccination Vaccine Development Clinical Trials 307

Delveinsight

DECEMBER 13, 2020

Even though clinical trial results were promising, adverse events and serious complications were observed. HBV DNA can be integrated into the host genome. New antiviral drugs in clinical trials include entry receptor inhibitors, capsid assembly modifiers, RNA interference, and nucleic acid polymers.

Genotype 52

Genotype FDA Approval DNA Drugs 52

Drug Discovery World

OCTOBER 6, 2022

Jarret Glasscock , PhD, CEO of Cofactor Genomics explains how diagnostics are emerging as the key to ensuring the right patients get matched to the right therapy, at the right time. . In the cancer space alone over the last five years, clinical trials have increased 500% for new drugs and new drug combinations.

Medicine 52

Medicine Clinical Trials Clinical Trials Genome 52

Drug Discovery World

DECEMBER 15, 2022

Now, after nearly 35 years of research and more than a decade of preclinical progress, several different gene editing modalities are being tested in early phase clinical trials. Early phase clinical trials for gene editing therapies. Gene editing challenges and potential solutions. Expand representation across global populations.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

Drug Discovery World

MARCH 13, 2023

The data confirms the good overall safety profile of the product in terms of systemic and ocular tolerability, humoral and cellular immune response. Almost all patients (95%) received lenadogene nolparvovec at a dose of 9 x 1010 viral genomes per eye and 88% had at least two years of follow-up.

Gene Therapy 52

Gene Therapy Gene Immune Response Genome 52

The Pharma Data

APRIL 11, 2021

Opdivo- based therapies have now demonstrated positive results in Phase 3 trials in earlier stages of four different types of cancer: non-small cell lung cancer, esophageal/gastroesophageal junction cancer, bladder cancer and melanoma. Surgery was rarely canceled due to adverse events, only affecting two patients in each arm of the trial.

Trials 52

Trials Immune Response Genome Genomics 52

Drug Discovery World

SEPTEMBER 6, 2022

And whilst clinical trials activity decreased by around 15% compared to 2020, last year still saw a number of regenerative medicines reach the bedside. Research into genomic medicines is only at its infancy. Last year saw the sector surge, with levels of investment hitting an all-time high at $22.7 billion, compared to $19.9

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

Drug Discovery World

FEBRUARY 6, 2023

It’s a rapid growth area for clinical trials in the next few years as we seek to understand the underlying biology behind many of the targets and diseases we study. For example, we recently collaborated with two sequencing laboratories to determine optimal parameters for RNA-Sequencing (RNA-Seq) in the context of a vaccine clinical trial.

Big Data 52

Big Data RNA Bioinformatics Vaccination 52

The Pharma Data

AUGUST 11, 2020

.–( BUSINESS WIRE )– Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -577 trial evaluating Opdivo (nivolumab) as an adjuvant therapy for patients with resected esophageal or gastroesophageal junction (GEJ) cancer met its primary endpoint of disease-free survival (DFS) at a pre-specified interim analysis.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

The safety profiles of Opdivo and chemotherapy in this trial are reflective of the known safety profiles of Opdivo and chemotherapy in first-line gastric and esophageal cancers. The company remains blinded to data from this arm and the trial continues in follow-up to allow the data to mature. PRINCETON, N.J.–(

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

JUNE 30, 2021

Approval based on Phase 2 CheckMate -142 trial results showing nearly two-thirds of patients responded to the Opdivo plus Yervoy combination with durable responses observed. Results from the CheckMate -142 trial at minimum follow-up of 46.9 achieving a complete response. CheckMate -142 Efficacy and Safety Results.

Trials 52

Trials Genome Genomics Containment 52

Drug Discovery World

AUGUST 1, 2023

The NIH states: “This natural mechanism for sequence-specific gene silencing promises to revolutionise experimental biology and may have important practical applications in functional genomics, therapeutic intervention, agriculture and other areas.” There are many examples of ways in which RNAi is impacting drug discovery.

RNA 52

RNA Drugs Gene Silencing Vaccination 52

The Pharma Data

JANUARY 4, 2021

Food and Drug Administration (FDA) , in combination with Tecentriq ® (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression with no EGFR or ALK genomic tumor aberrations. chief medical officer and head of Global Product Development. “We

Immune Response 52

Immune Response Medicine Protein Gene 52

Pharma Marketing Network

JANUARY 20, 2021

It’s widely acknowledged that optimal vaccine immunity results from engaging both humoral and cellular responses, but less attention has been given to the role of mucosal immunity in protecting against COVID-19, which is surprising considering SARS-CoV-2 enters the human body primarily through the mucosal surfaces of the upper respiratory tract.

Vaccination 52

Vaccination Vaccine In-Vivo Genetics 52

The Pharma Data

OCTOBER 14, 2020

(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the observational PRECISION study (TNX-C002), to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. About TNX-1800.

Vaccination 40

Vaccination Vaccine Development Medicine 40

The Pharma Data

MARCH 11, 2021

The accelerated approval was based on tumor responses from the Phase 1/2 CheckMate -040 trial. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response.

Trials 52

Trials Hormones Genome Genomics 52

The Pharma Data

JULY 23, 2021

The accelerated approval was based on tumor responses from the Phase 1/2 CheckMate -040 trial. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response.

Hormones 52

Hormones Trials Genome Genomics 52

Drug Discovery World

SEPTEMBER 29, 2022

After the initial infection, CMV becomes latent, with the genome residing in cells but no virus particles generated to cause detectable damage or illness 7,8. Latent CMV may reactivate occasionally, leading to infection, which is often asymptomatic in individuals with healthy immune systems though still transmissible to others 7. .

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

Pfizer

NOVEMBER 2, 2022

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the advancement of an mRNA-based combination vaccine candidate for influenza and COVID-19 to a Phase 1 trial with the aim to address two severe respiratory diseases with one vaccine.

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

The Pharma Data

DECEMBER 29, 2020

29, 2020 — Vaccine maker Novavax, along with federal health researchers, announced Monday that a phase 3 trial will begin on the safety and effectiveness of another COVID-19 vaccine — the fifth shot to reach this final stage of development. TUESDAY, Dec. Uptick in vaccine acceptance. “It may very well be here.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52